公开(公告)号：US20220071951A1

公开(公告)日：2022-03-10

申请号：US17419100

申请日：2019-12-27

Applicant: OSAKA UNIVERSITY ,  NISSAN CHEMICAL CORPORATION

Inventor： Yoshihiro ASANO ,  Seiji TAKASHIMA ,  Noriaki YAMADA ,  Toru YAMASHITA

IPC: A61K31/353 ,  A61P9/06 ,  A61K31/4741

Abstract: A therapeutic agent for bradyarrythmia contains the following compound (I) or compound (II) or a pharmacologically acceptable salt thereof as an active component: (wherein, Ph is a phenyl group).

公开(公告)号：US20240008761A1

公开(公告)日：2024-01-11

申请号：US18265040

申请日：2021-11-25

Applicant: OSAKA UNIVERSITY

Inventor： Hidetaka KIOKA ,  Yusuke TAKAHASHI ,  Shinichiro FUKUHARA ,  Yasushi SAKATA ,  Norio NONOMURA ,  Seiji TAKASHIMA ,  Shigeyoshi SAITO

IPC: A61B5/055 ,  G01R33/485 ,  A61B5/00

CPC classification number: A61B5/055 ,  G01R33/485 ,  A61B5/4387

Abstract: An evaluation method is performed by an arithmetic circuit and includes obtainment processing (S1), evaluation processing (S2), and presentation processing (S3). The obtainment processing (S1) obtains: image information on a sectional image representing an interested section of an organism including a target section of a testis of the organism generated by use of magnetic resonance of hydrogen atoms; and concentration information on a creatine concentration in the interested section measured by use of magnetic resonance based on chemical exchange saturation transfer. The evaluation processing (S2) generates an evaluation image representing a distribution of evaluation results of a testicular function in the target section based on the concentration information. The presentation processing (S3) presents the sectional image and the evaluation image.

公开(公告)号：US20220378943A1

公开(公告)日：2022-12-01

申请号：US17775780

申请日：2020-11-12

Applicant: OSAKA UNIVERSITY

Inventor： Seiji TAKASHIMA ,  Ken MATSUOKA ,  Yoshihiro ASANO ,  Osamu TSUKAMOTO ,  Hidetaka KIOKA

IPC: A61K48/00 ,  A61K35/76 ,  C12N15/63 ,  A61P9/04

Abstract: The object of the present invention is to provide a polynucleotide which can be inserted into an expression vector and can enhance the transcriptional activity of a predetermined promoter under heart failure.
The object is achieved by an enhancer polynucleotide comprising a polynucleotide consisting of a sequence having 80% or more identity with a sequence represented by SEQ ID NO: 1, or a polynucleotide consisting of a sequence having 80% or more identity with a sequence represented by SEQ ID NO: 2, wherein the enhancer polynucleotide responds to heart failure (where the enhancer polynucleotide excludes a polynucleotide having the same sequence as a sequence represented by SEQ ID NO: 13 and a polynucleotide having the same sequence as a sequence represented by SEQ ID NO: 12).

公开(公告)号：US20230248694A1

公开(公告)日：2023-08-10

申请号：US18134609

申请日：2023-04-14

Applicant: OSAKA UNIVERSITY ,  NISSAN CHEMICAL CORPORATION

Inventor： Yoshihiro ASANO ,  Seiji TAKASHIMA ,  Noriaki YAMADA ,  Toru YAMASHITA

IPC: A61K31/353 ,  A61P9/06 ,  A61K31/4741

CPC classification number: A61K31/353 ,  A61P9/06 ,  A61K31/4741

Abstract: A method of treating bradyarrhythmia includes administering to a patient having bradyarrhythmia a therapeutically effective amount of at least one of compound (I) and compound (II) or pharmacologically acceptable salts thereof as an active component:




wherein Ph is a phenyl group.

公开(公告)号：US20230241053A1

公开(公告)日：2023-08-03

申请号：US18013174

申请日：2021-06-25

Applicant: OSAKA UNIVERSITY ,  NISSAN CHEMICAL CORPORATION

Inventor： Seiji TAKASHIMA ,  Yoshihiro ASANO ,  Noriaki YAMADA ,  Yoshiki KONDO ,  Yu KAWAI

IPC: A61K31/4741 ,  A61P9/06

CPC classification number: A61K31/4741 ,  A61P9/06

Abstract: A therapeutic agent for drug-induced bradycardia and bradyarrhythmia. A therapeutic agent for drug-induced bradycardia and bradyarrhythmia including, as an active ingredient, the following compound (I):




(wherein Ph is a phenyl group) or a pharmacologically acceptable salt of the compound.